<DOC>
	<DOCNO>NCT01865292</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacodynamics ( effect investigate drug body ) pharmacokinetics ( exposure trial drug body ) insulin degludec ( insulin 454 ) , explorative formulation , similar propose commercial formulation , insulin glargine subject type 1 type 2 diabetes .</brief_summary>
	<brief_title>Comparing Pharmacodynamics Pharmacokinetics Explorative Formulation Insulin Degludec With Insulin Glargine Subjects With Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Glycosylated haemoglobin ( HbA1c ) equal 10 procent base central laboratory result Specific inclusion criterion subject type 1 diabetes : Diagnosed type 1 diabetes mellitus treat insulin least 12 month prior screen Body Mass Index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Specific inclusion criterion subject type 2 diabetes : Diagnosed type 2 diabetes mellitus least 12 month prior screen Treated insulin past 3 month prior screen Body Mass Index ( BMI ) 22.0 35.0 kg/ m^2 ( inclusive ) Subject history significant multiple drug allergy know allergy suspect allergy trial product medicine chemically related trial product , judged Investigator . Subject history presence cancer Any condition Investigator and/or Sponsor feel would interfere study Specific exclusion criterion subject type 2 diabetes : Therapy oral antidiabetic drug within past 3 month prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>